Key facts
- Rybelsus is semaglutide tablets, a once-daily GLP-1 receptor agonist from Novo Nordisk, FDA approved on 20 September 2019 for type 2 diabetes (NDA 213051).[2][1]
- On 30 January 2026 the FDA approved renaming the newer formulation (1.5, 4 and 9 mg) from Rybelsus to Ozempic tablets; it went on sale in the US on 4 May 2026.[5][7]
- The FDA record still lists Rybelsus 3, 7 and 14 mg as prescription products, and Novo says Rybelsus will continue to be marketed outside the US; US patients are being moved to Ozempic tablets with a new prescription.[2][7][8]
- Rybelsus is not approved for weight loss. In PIONEER 1, the 14 mg dose cut weight by 3.7 kg over 26 weeks against 1.4 kg on placebo.[1][13]
- The two tablet ranges are not substitutable mg for mg: Rybelsus 7 mg matches Ozempic tablets 4 mg, and 14 mg matches 9 mg.[1]
Rybelsus vs Ozempic Tablets vs Ozempic Injection vs Wegovy Pill
All four contain semaglutide from Novo Nordisk, but Rybelsus (3, 7, 14 mg) and Ozempic tablets (1.5, 4, 9 mg) are daily pills for type 2 diabetes, Ozempic injection (0.25 to 2 mg) is a weekly shot for type 2 diabetes, and the Wegovy pill (up to 25 mg daily) is the only one of the four approved for weight loss.[1][9][11]
| Feature | Rybelsus | Ozempic tablets | Ozempic injection | Wegovy pill |
|---|---|---|---|---|
| Active ingredient | Semaglutide[1] | Semaglutide[1] | Semaglutide[9] | Semaglutide[11] |
| Form and frequency | Tablet, once daily[1] | Tablet, once daily[1] | Injection under the skin, once weekly[9] | Tablet, once daily[11] |
| Strengths | 3, 7, 14 mg[1] | 1.5, 4, 9 mg[1] | 0.25, 0.5, 1, 2 mg doses[9] | 1.5, 4, 9, 25 mg[12] |
| Main approved use | Type 2 diabetes: blood sugar and cardiovascular risk[1] | Same label as Rybelsus[1] | Type 2 diabetes: blood sugar, cardiovascular and kidney risk[9] | Weight management and cardiovascular risk in obesity[11] |
| Approved for weight loss | No[1] | No[1] | No[9] | Yes[11] |
| First US approval | 20 Sep 2019[2] | Formulation 9 Dec 2024; name 30 Jan 2026[3][5] | 5 Dec 2017[10] | 22 Dec 2025[12] |
| Application | NDA 213051[2] | NDA 213051[2] | NDA 209637[10] | NDA 218316[12] |
Rybelsus and other prescription semaglutide products are not sold in this shop, and this page is not a guide to obtaining them. It summarises FDA records, Novo Nordisk statements and published trials for reference. For every approved GLP-1 tablet side by side see GLP-1 pills compared, and for the 25 mg weight-loss pill see the Wegovy pill.
What Is Rybelsus?
Rybelsus is the brand name for semaglutide tablets, a GLP-1 receptor agonist taken once a day by mouth in 3, 7 or 14 mg strengths, first approved by the FDA on 20 September 2019.[2][1]
| Feature | Rybelsus |
|---|---|
| Generic name | Semaglutide[1] |
| Maker | Novo Nordisk[1] |
| Drug class | GLP-1 receptor agonist[1] |
| Approved uses (US) | With diet and exercise to improve blood sugar in adults with type 2 diabetes; to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk[1] |
| Absorption enhancer | Co-formulated with SNAC; absorption happens mainly in the stomach[1] |
| Oral bioavailability | About 0.4% to 1% (Rybelsus); 1% to 2% (Ozempic tablets)[1] |
| Half-life | About one week[1] |
| Boxed warning | Risk of thyroid C-cell tumours[1] |
- What Rybelsus is used for: the label lists two uses, both in adults with type 2 diabetes: lowering blood sugar alongside diet and exercise, and reducing the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke in people at high risk.[1]
- The cardiovascular use was added on 17 October 2025, based on the SOUL trial, in the same FDA action that removed the type 1 diabetes limitation of use from the label.[4]
- The label has no weight-management indication, and safety and effectiveness in children have not been established.[1]
Rybelsus Renamed Ozempic Tablets: What Changed
On 30 January 2026 the FDA approved changing the name of the newer Rybelsus formulation, known as formulation R2 (1.5, 4 and 9 mg), to Ozempic tablets; the original 3, 7 and 14 mg Rybelsus tablets kept their name.[5][1]
| Date | Event |
|---|---|
| 20 Sep 2019 | FDA approves Rybelsus (semaglutide) tablets 3, 7 and 14 mg[2] |
| 9 Dec 2024 | FDA approves Rybelsus formulation R2, its own dosing schedule and rules for switching between R1 and R2 (supplement 20)[3] |
| 17 Oct 2025 | FDA adds the cardiovascular risk reduction indication (supplement 24)[4] |
| 30 Jan 2026 | FDA approves renaming formulation R2 from Rybelsus to Ozempic tablets (supplement 30)[5] |
| 4 Feb 2026 | Novo Nordisk announces the Ozempic tablets name and a filing for Ozempic tablets 25 mg in type 2 diabetes[6] |
| 4 May 2026 | Ozempic tablets 1.5, 4 and 9 mg become available in the US[7] |
- Same molecule, different tablet. Novo says the active ingredient remains the same semaglutide molecule, and that the 1.5, 4 and 9 mg formulation has the same efficacy and safety profile as the original, in a smaller pill.[6][7]
- Higher absorption. The new tablets deliver about 1% to 2% of the dose into the blood, against 0.4% to 1% for Rybelsus, so a lower mg dose gives the same exposure.[1]
- Matched by a bioequivalence study. In healthy volunteers there were no clinically significant differences in steady-state exposure between Rybelsus 3, 7 and 14 mg and Ozempic tablets 1.5, 4 and 9 mg respectively.[1]
- Why the rename. Novo says the Ozempic name is meant to help patients and clinicians recognise the type 2 diabetes options that contain semaglutide.[6]
- One shared label. Both products now sit on a single prescribing information document under NDA 213051.[1][2]
Is Rybelsus Being Discontinued?
Not on the FDA record: as of 8 November 2026, Drugs@FDA still lists Rybelsus 3, 7 and 14 mg with a marketing status of prescription, though Novo is moving US patients to Ozempic tablets and says Rybelsus will continue to be marketed outside the US.[2][7]
- Novo told Rybelsus patients to keep taking their medicine as directed and to talk to their healthcare professional about transitioning to the Ozempic pill, as appropriate.[7]
- The rybelsus.com home page tells patients that newly available doses of semaglutide tablets exist and to contact their healthcare professional for an updated prescription before current refills run out.[8]
- Novo describes the change as a name change from Rybelsus to the Ozempic pill, alongside new dosage strengths.[7]
- No FDA notice or Novo Nordisk statement opened for this page announces a US discontinuation date for Rybelsus 3, 7 or 14 mg.[2][7]
Rybelsus Dose: 3 mg, 7 mg and 14 mg vs Ozempic Tablets
Rybelsus starts at 3 mg once daily for 30 days, rises to 7 mg, and can go to 14 mg from day 61 if more blood sugar control is needed; Ozempic tablets follow the same steps at 1.5 mg, 4 mg and 9 mg.[1]
| Phase | Rybelsus | Ozempic tablets |
|---|---|---|
| Days 1 to 30 (start) | 3 mg once daily | 1.5 mg once daily |
| Days 31 to 60 | 7 mg once daily | 4 mg once daily |
| Day 61 onward, enough control | Stay on 7 mg | Stay on 4 mg |
| Day 61 onward, more control needed | 14 mg once daily | 9 mg once daily[1] |
- Rybelsus 3 mg is a starter dose only: the label says it is not effective for glycaemic control. The same applies to Ozempic tablets 1.5 mg.[1]
- The step-up schedule is there to reduce the risk of gastrointestinal side effects.[1]
- Take no more than one tablet a day.[1]
- Novo has filed for an Ozempic tablets 25 mg dose in type 2 diabetes and expects an FDA decision by the end of 2026; as of 8 November 2026 Drugs@FDA lists no 25 mg Ozempic tablet.[7][2]
Rybelsus to Ozempic Conversion
The label pairs Rybelsus 7 mg with Ozempic tablets 4 mg and Rybelsus 14 mg with Ozempic tablets 9 mg, starting the new product the day after the last dose of the old one, and only after the first 30 days.[1]
| Switching from | Switching to | Label rule |
|---|---|---|
| Rybelsus 7 mg daily | Ozempic tablets 4 mg daily | Start the next day[1] |
| Rybelsus 14 mg daily | Ozempic tablets 9 mg daily | Start the next day[1] |
| Rybelsus 3 mg or Ozempic tablets 1.5 mg (days 1 to 30) | The other tablet | Do not switch during the 30-day starting phase[1] |
| Ozempic injection 0.5 mg weekly | Rybelsus 7 mg or 14 mg daily | Start one week after the last injection[1] |
| Ozempic injection 0.5 mg weekly | Ozempic tablets 4 mg or 9 mg daily | Start one week after the last injection[1] |
The tablet label only covers switching from the 0.5 mg Ozempic injection to tablets. It gives no conversion from the 1 mg or 2 mg injection doses, and no rule for moving from tablets back to the injection.[1]
How to Take Rybelsus
The label says to take one tablet in the morning on an empty stomach with no more than 4 ounces (about 120 ml) of plain water, then wait at least 30 minutes before eating, drinking or taking other oral medicines.[1]
- Swallow the tablet whole; do not split, crush, chew or dissolve it.[1]
- Do not take it with any liquid other than water.[1]
- If a dose is missed, skip it and take the next dose the following day.[1]
- Why the rules matter: in label studies, semaglutide absorption was higher with less water and with a longer fasting period after the dose.[1]
- Rybelsus slows stomach emptying, so the label advises closer monitoring for other oral medicines with a narrow therapeutic index.[1]
The Wegovy pill uses the same morning, empty-stomach, 30-minute routine. See Wegovy pill dosage for its own step-up schedule.[11]
Rybelsus Weight Loss in the PIONEER Trials
In the 26-week PIONEER 1 trial, Rybelsus 14 mg lowered body weight by 3.7 kg from about 88 kg, against 1.4 kg on placebo, but Rybelsus is approved for type 2 diabetes, not weight loss.[1][13]
Label Table 4 trial (NCT02906930), adults with type 2 diabetes on diet and exercise only. Treatment-policy estimand.
| Trial | Comparator | Rybelsus | Comparator result |
|---|---|---|---|
| PIONEER 1 (n = 703) | Placebo | -2.3 kg (7 mg), -3.7 kg (14 mg) | -1.4 kg[1] |
| PIONEER 2 (n = 822) | Empagliflozin 25 mg | -3.8 kg (14 mg) | -3.7 kg[1][14] |
| PIONEER 3 (n = 1,864) | Sitagliptin 100 mg | -2.2 kg (7 mg), -3.1 kg (14 mg) | -0.6 kg[1][15] |
| PIONEER 4 (n = 711) | Liraglutide 1.8 mg injection or placebo | -4.4 kg (14 mg) | -3.1 kg liraglutide; -0.5 kg placebo[1][16] |
- In PIONEER 1, weight loss was statistically superior to placebo only at 14 mg: the placebo-adjusted difference was -2.3 kg (14 mg), -0.9 kg (7 mg) and -0.1 kg (3 mg).[13]
- In PIONEER 4, the only label trial against an injectable GLP-1, Rybelsus 14 mg gave more weight loss than liraglutide 1.8 mg at 26 weeks: -4.4 kg against -3.1 kg.[16]
- Rybelsus dose for weight loss: there is no approved one. The oral semaglutide dose approved for weight management is the Wegovy pill 25 mg, which gave 13.6% weight loss at 64 weeks in OASIS 4 against 2.4% on placebo, in adults with obesity or overweight.[11][19]
The PIONEER trials enrolled adults with type 2 diabetes and measured weight as a secondary outcome over 26 weeks, so their results should not be read as a weight-loss programme. For weight-focused oral options see the Wegovy pill and Foundayo vs the Wegovy pill.
Rybelsus Side Effects
Nausea affected 11% of people on Rybelsus 7 mg and 20% on 14 mg in the label’s placebo-controlled pool, against 6% on placebo, and 4% to 8% stopped because of gastrointestinal side effects (placebo 1%).[1]
| Adverse reaction | Placebo (n = 362) | 7 mg (n = 356) | 14 mg (n = 356) |
|---|---|---|---|
| Nausea | 6% | 11% | 20% |
| Abdominal pain | 4% | 10% | 11% |
| Diarrhoea | 4% | 9% | 10% |
| Decreased appetite | 1% | 6% | 9% |
| Vomiting | 3% | 6% | 8% |
| Constipation | 2% | 6% | 5%[1] |
- Any gastrointestinal reaction: 41% on 14 mg and 32% on 7 mg against 21% on placebo; severe GI reactions 2.0%, 0.6% and 0.3%. Most nausea, vomiting and diarrhoea happened during dose escalation.[1]
- In the 4-year SOUL cardiovascular trial, 15.5% on semaglutide tablets stopped for an adverse event against 11.6% on placebo.[1]
- The label carries a boxed warning on thyroid C-cell tumours and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2.[1]
- Other warnings: acute pancreatitis, diabetic retinopathy complications, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration, severe GI reactions, allergic reactions, gallbladder disease and aspiration during anaesthesia.[1]
- The label advises stopping at least 2 months before a planned pregnancy because of semaglutide’s long washout, and does not recommend breastfeeding.[1]
For the side-effect profile of the 25 mg weight-loss tablet, see Wegovy pill side effects.
Rybelsus and Heart Risk (SOUL Trial)
In SOUL, 9,650 adults with type 2 diabetes and heart or kidney disease were followed for a median 49.5 months, and major cardiovascular events occurred in 12.0% on Rybelsus 14 mg against 13.8% on placebo (hazard ratio 0.86).[17][1]
| Outcome | Placebo (n = 4,825) | Semaglutide tablets 14 mg (n = 4,825) | Hazard ratio (95% CI) |
|---|---|---|---|
| MACE (CV death, non-fatal MI, non-fatal stroke) | 13.8% | 12.0% | 0.86 (0.77 to 0.96) |
| Cardiovascular death | 6.6% | 6.2% | 0.93 (0.80 to 1.09) |
| Non-fatal heart attack | 5.2% | 4.0% | 0.74 (0.61 to 0.89) |
| Non-fatal stroke | 3.3% | 3.0% | 0.88 (0.70 to 1.11)[1] |
The NEJM report found no significant difference on the confirmatory secondary outcomes, which included major kidney disease events, and serious adverse events were 47.9% on oral semaglutide against 50.3% on placebo.[17]
Rybelsus vs Ozempic and Rybelsus vs Wegovy
Rybelsus is a daily semaglutide pill of up to 14 mg for type 2 diabetes, Ozempic is the same drug as a weekly injection of up to 2 mg (and now also a daily tablet), and the Wegovy pill is a daily 25 mg semaglutide tablet approved for weight management.[1][9][11]
- Is Rybelsus the same as Ozempic? The same molecule, yes. Ozempic injection and Rybelsus are separate products under separate applications, while Ozempic tablets share Rybelsus’ application and label.[2][10][1]
- Uses differ. Ozempic injection also carries a kidney outcome indication in type 2 diabetes with chronic kidney disease; the tablet label does not.[9][1]
- Routine differs. Ozempic injection is taken once weekly at any time, with or without meals; the tablets need an empty stomach, little water and a 30-minute wait every day.[9][1]
- Rybelsus vs Wegovy pill. Both are oral semaglutide with the same dosing routine, but the Wegovy pill steps up from 1.5 mg to a 25 mg maintenance dose and is indicated for weight management, while Rybelsus tops out at 14 mg and is indicated for type 2 diabetes.[11][1]
- No head-to-head trial of Rybelsus against Ozempic injection or the Wegovy pill was found in the sources checked for this page. The one oral head-to-head trial is ACHIEVE-3, where orforglipron beat oral semaglutide 7 and 14 mg on HbA1c in type 2 diabetes.[18] See what is orforglipron.
For prices of the weight-loss tablet see Wegovy pill price. For how semaglutide compares with Lilly’s investigational amylin drug see eloralintide vs semaglutide, and for non-GLP-1 approaches see GLP-1 alternatives.
Frequently Asked Questions
What is Rybelsus used for?
Rybelsus is used in adults with type 2 diabetes, alongside diet and exercise, to improve blood sugar control, and to reduce the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke in people at high risk of these events. It is not approved for weight loss, and its safety and effectiveness in children have not been established.
Is Rybelsus being discontinued?
Not on the FDA record. As of 8 November 2026 Drugs@FDA still lists Rybelsus 3, 7 and 14 mg as prescription products. In the US, Novo Nordisk is moving patients to Ozempic tablets 1.5, 4 and 9 mg, available since 4 May 2026, and asks Rybelsus patients to talk to their prescriber about transitioning. Novo says Rybelsus will continue to be marketed outside the US.
Is Rybelsus the same as Ozempic?
Both contain semaglutide. Ozempic injection is a once-weekly shot; Rybelsus is a once-daily tablet. Since 30 January 2026 the newer 1.5, 4 and 9 mg semaglutide tablet formulation is called Ozempic tablets, which shares a label with Rybelsus but is not interchangeable with it mg for mg.
What is the Rybelsus generic name?
Semaglutide. Rybelsus is the brand name for semaglutide tablets made by Novo Nordisk; the same active ingredient is in Ozempic tablets, Ozempic injection and Wegovy.
What is Rybelsus 3 mg for?
Rybelsus 3 mg is the starting dose, taken once daily for the first 30 days to reduce gastrointestinal side effects before moving to 7 mg. The label states that 3 mg is not effective for blood sugar control on its own.
What is the Rybelsus to Ozempic conversion?
Under the FDA label, Rybelsus 7 mg converts to Ozempic tablets 4 mg and Rybelsus 14 mg converts to Ozempic tablets 9 mg, starting the day after the last Rybelsus dose. Switching is not recommended during the first 30 days. From Ozempic injection 0.5 mg weekly, the label allows a switch to Rybelsus 7 or 14 mg, or Ozempic tablets 4 or 9 mg, one week after the last injection.
How do you take Rybelsus?
Once a day in the morning on an empty stomach, with up to 4 ounces of plain water. Swallow the tablet whole and wait at least 30 minutes before eating, drinking or taking other oral medicines. If a dose is missed, skip it and take the next one the following day.
Does Rybelsus cause weight loss?
People lost some weight in the diabetes trials: 3.7 kg on 14 mg against 1.4 kg on placebo over 26 weeks in PIONEER 1, and 4.4 kg on 14 mg in PIONEER 4. Rybelsus is not approved for weight loss, and there is no approved Rybelsus dose for weight loss. The oral semaglutide approved for weight management is the Wegovy pill at 25 mg.
Rybelsus vs Wegovy: what is the difference?
Both are semaglutide. Rybelsus is a tablet of up to 14 mg for type 2 diabetes. Wegovy comes as a weekly injection or a daily tablet stepping up to 25 mg, and is approved for weight management and for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight.
What are the side effects of Rybelsus?
Mostly digestive. In the label’s placebo-controlled pool, nausea affected 11% on 7 mg and 20% on 14 mg (placebo 6%), with abdominal pain, diarrhoea, decreased appetite, vomiting and constipation also common. The label carries a boxed warning on thyroid C-cell tumours.
Sources
- FDA. RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information, revised 01/2026 (NDA 213051, supplement 30), checked 8 Nov 2026
- openFDA Drugs@FDA record, NDA 213051 (Rybelsus and Ozempic tablets): approval history, products and marketing status, checked 8 Nov 2026
- FDA. NDA 213051/S-020 and S-021 supplement approval letter, 9 Dec 2024: Rybelsus formulation R2 and switching, checked 8 Nov 2026
- FDA. NDA 213051/S-024, S-028 and S-029 supplement approval letter, 17 Oct 2025: cardiovascular risk reduction indication, checked 8 Nov 2026
- FDA. NDA 213051/S-030 supplement approval letter, 30 Jan 2026: name change from Rybelsus (formulation R2) to Ozempic tablets, checked 8 Nov 2026
- Novo Nordisk press release, 4 Feb 2026: FDA approves Ozempic tablets as the name for oral semaglutide 1.5, 4 and 9 mg, checked 8 Nov 2026
- Novo Nordisk press release, 1 May 2026: Ozempic pill US availability from 4 May 2026, checked 8 Nov 2026
- Novo Nordisk, rybelsus.com home page notice on newly available semaglutide tablet doses, checked 8 Nov 2026
- openFDA drug label, OZEMPIC (semaglutide) injection, NDA 209637, label effective 30 Jul 2026, checked 8 Nov 2026
- openFDA Drugs@FDA record, NDA 209637 (Ozempic injection): approval 5 Dec 2017, products, checked 8 Nov 2026
- FDA. WEGOVY (semaglutide) injection and tablets prescribing information, revised 06/2026 (NDA 218316, supplement 7), checked 8 Nov 2026
- openFDA Drugs@FDA record, NDA 218316 (Wegovy tablets): approval 22 Dec 2025, products and marketing status, checked 8 Nov 2026
- Aroda VR, et al. PIONEER 1: oral semaglutide monotherapy vs placebo in type 2 diabetes. Diabetes Care 2019;42(9):1724-1732. DOI 10.2337/dc19-0749, checked 8 Nov 2026
- Rodbard HW, et al. Oral semaglutide vs empagliflozin in type 2 diabetes uncontrolled on metformin (PIONEER 2). Diabetes Care 2019;42(12):2272-2281. DOI 10.2337/dc19-0883, checked 8 Nov 2026
- Rosenstock J, et al. Additional oral semaglutide vs sitagliptin in type 2 diabetes (PIONEER 3). JAMA 2019;321(15):1466-1480. DOI 10.1001/jama.2019.2942, checked 8 Nov 2026
- Pratley R, et al. Oral semaglutide vs subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4). The Lancet 2019;394(10192):39-50. DOI 10.1016/S0140-6736(19)31271-1, checked 8 Nov 2026
- McGuire DK, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL). N Engl J Med 2025;392(20):2001-2012. DOI 10.1056/NEJMoa2501006, checked 8 Nov 2026
- Rosenstock J, et al. Once-daily oral orforglipron compared with oral semaglutide in type 2 diabetes (ACHIEVE-3). The Lancet 2026;407(10534):1147-1160. DOI 10.1016/S0140-6736(26)00202-3, checked 8 Nov 2026
- Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med 2025;393(11):1077-1087. DOI 10.1056/NEJMoa2500969, checked 8 Nov 2026
For research use only. Not for human or veterinary consumption. This guide summarises published research for information only. It is not medical advice and does not describe any use of products sold on this site.